Merck Joins Forces to Improve Access to Ebola Vaccine Worldwide

Merck, a global leader in pharmaceuticals, has announced a new partnership with a prominent global health coalition to make its life-saving Ebola vaccine more affordable and accessible.

They desire to support areas that are most affected by Ebola to have more people against the harmful virus.

The strategy is aimed at ensuring that Merck Ebola vaccine, Ervebo is improved. The companies also desire to reduce the price in order to make it accessible to poorer countries at a cheaper cost. Merck will also strive more to deliver the vaccine to the outbreak prone places.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

"We believe this partnership will bring real change to communities affected by Ebola," said Dr. Julie L. Gerberding, Executive Vice President of Merck. "By making this vaccine more affordable, we can save lives and stop outbreaks faster."

This collaboration comes in handy with the war against Ebola, particularly in nations that lack adequate health care. It demonstrates the commitment of Merck to benefit the whole world by ensuring that those who require the protection most do not lag behind. The work would prevent future outbreaks and reduce the horrible impacts of the disease.